A Double Punch for Plasma Cell Leukemia: What the Latest Transplant Research Means for Patients

Table of Contents

• Key Points
• What Is Plasma Cell Leukemia?
• About the Study: 751 Patients from a European Registry
• Key Findings: Which Transplant Strategy Worked Best?
• Timing Matters: Complete Response After Induction
• Overall Survival: A More Complicated Picture
• The Relapse Problem: Most Patients Relapsed Within 2–3 Years
• Maintenance After Transplant: Two Open Questions
• The Graft-Versus-Host Disease Barrier
• Future Treatment Options: New Immunotherapies
• Clinical Trials That Include pPCL Patients
• Clinical Implications: What This Means for Patients
• Limitations: What This Study Couldn't Prove
• Recommendations for Patients and Families
• Source Information
• Frequently Asked Questions

Key Points

• Tandem auto-auto showed a nominal but non-significant progression-free survival improvement; overall survival differences for tandem approaches did not reach statistical significance.
• Patients achieving complete response after induction had longer progression-free survival with auto-auto than auto-allo, suggesting response depth should guide transplant choice.
• New immunotherapies show promise in myeloma, but their safety and activity in pPCL remain unproven; clinical trial enrollment is critically important.

What Is Plasma Cell Leukemia?

To understand this research, it helps to start with the basics. Multiple myeloma is a cancer of plasma cells, the antibody-producing white blood cells that normally live in the bone marrow. Primary plasma cell leukemia (pPCL) is a rare and much more aggressive version of that disease, in which malignant plasma cells escape the bone marrow and circulate in the bloodstream.

Plasma cell leukemia is severely understudied. Many new therapies have recently been approved for multiple myeloma, but the editorial author, Professor Martin Kaiser of The Institute of Cancer Research and The Royal Marsden Hospital in London, notes that this progress "makes it easy to forget" that pPCL still has very few evidence-based treatment options.

Why has research lagged behind? Two major barriers stand out. First, pPCL is extremely rare, making large clinical trials difficult to organize. Second, the disease is so aggressive that there is urgent pressure to start therapy, leaving little time to enroll patients in studies. As a result, treatment approaches for pPCL have often been "laterally adopted" from myeloma practice — meaning doctors apply what works for myeloma and hope it works for pPCL.

Intensive therapy including a stem cell transplant remains the standard of care for younger pPCL patients in many healthcare systems. But doctors have had surprisingly little solid data comparing transplant strategies in this specific disease.

About the Study: 751 Patients from a European Registry

In this data-poor field, the work by Lawless, Iacobelli and colleagues, published in this issue of the journal Haematologica, offers highly welcome evidence. The researchers drew their data from the registry of the European Group for Blood and Marrow Transplantation (EBMT). This registry has provided invaluable insights into rare blood cancers like pPCL long before "real-world data" became fashionable, the editorial notes.

The analysis included 751 pPCL patients treated between 1998 and 2014. The editorial points out that this period is known as the "pre-maintenance therapy era" — meaning it predates the routine use of maintenance drugs designed to keep cancer in remission after transplant.

The researchers compared four transplant strategies:

• Single autologous transplant (single auto) — the patient's own stem cells are collected, high-dose chemotherapy is given, and the stem cells are returned to rebuild the bone marrow.
• Single allogeneic transplant (single allo) — stem cells from a donor (another person) are used instead of the patient's own cells.
• Tandem auto-auto — two consecutive autologous transplants using the patient's own stem cells.
• Tandem auto-allo — an autologous transplant first, followed by an allogeneic (donor) transplant. This is the "double punch" approach.

The study focused especially on whether tandem transplants were better than single transplants. It also compared the two tandem approaches against each other — something that had not been studied in this level of detail in pPCL before.

Researchers used statistical methods to adjust for differences in patient characteristics at baseline. They also used dynamic prediction modeling, a mathematical approach that estimates how patients fare over time.

Key Findings: Which Transplant Strategy Worked Best?

The main answer is clear: patients treated with tandem auto-allo showed the greatest improvement in progression-free survival (PFS) compared with those who received a single autologous transplant. PFS is the length of time a patient lives without the cancer growing or returning.

The other tandem approach also appeared to help, but less convincingly:

• Patients who underwent tandem auto-auto showed a nominal but non-significant improvement in PFS over those who received a single auto transplant. In plain language, the numbers looked better, but the difference was not strong enough to rule out the possibility that it happened by chance.
• By contrast, the improvement seen with auto-allo over single auto was statistically meaningful after adjusting for other factors.

The editorial emphasizes two encouraging points about auto-allo recipients. They had longer progression-free survival, and they had reduced non-relapse mortality — that is, fewer deaths from causes other than the cancer itself, such as infections or treatment complications.

The editorial authors believe these benefits are "likely to still hold up" even when patients receive modern induction therapies (the initial treatment given before transplant). In other words, the advantage of auto-allo may not be erased by today's stronger pre-transplant drug combinations.

Timing Matters: Complete Response After Induction

One of the most interesting findings concerns timing. Induction therapy aims to shrink or eliminate the cancer before transplant. A complete response (CR) means that no detectable signs of cancer remain after induction.

The modeling suggested that patients who achieved a complete response after induction had longer progression-free survival with auto-auto than with auto-allo. That finding may surprise some readers, because auto-allo came out ahead overall.

However, the research also showed this: when either tandem strategy was used during a time of complete response, patients had longer progression-free survival than patients who received a single auto transplant or an auto-allo transplant without having achieved a complete response after induction.

What does this mean? The patient's depth of response to induction therapy is a crucial factor in choosing a transplant strategy. Someone who achieves CR may do very well with a second autologous transplant, avoiding the extra risks of donor cells. Someone who does not reach CR may need the more powerful anti-cancer effect of an allogeneic transplant.

Overall Survival: A More Complicated Picture

Overall survival (OS) — the time until death from any cause — told a somewhat different story than progression-free survival. Overall survival was nominally improved by the tandem approaches, but the difference over a single auto transplant did not reach statistical significance.

This means the survival advantage could not be definitively proven from the data. Patients and doctors should understand that "not statistically significant" does not mean the treatment failed. It means the observed difference was too small, or the patient numbers too limited, to be certain the result was not due to chance.

Single allogeneic transplants produced results that the editorial describes as clinically unacceptable. Patients receiving single allo had high and early non-relapse mortality — in plain terms, a substantial number of patients died early from transplant complications rather than from the leukemia.

Auto-allo was a different story. Non-relapse mortality was markedly lower with auto-allo than with single allo. Yet here is the puzzle: the long-term overall survival of patients treated with the two strategies was similar. Also similar were the rates of acute and chronic graft-versus-host disease.

Graft-versus-host disease (GvHD) occurs when the donor's immune cells (the graft) recognize the patient's body (the host) as foreign and attack healthy tissues. Acute GvHD typically appears soon after transplant; chronic GvHD develops later and can last for months or years, affecting the skin, liver, mouth, eyes, and other organs.

The Relapse Problem: Most Patients Relapsed Within 2–3 Years

Despite the encouraging progression-free survival results, a sobering reality emerges from the data. The editorial states plainly: "the majority of pPCL patients in this study still relapsed within 2-3 years after auto-allo."

This outcome highlights the general need for post-transplant maintenance strategies. Maintenance therapy is long-term, lower-intensity treatment given after a transplant to delay or prevent relapse. In myeloma practice, maintenance has become routine. For pPCL, the best approach remains unclear.

Even the best transplant strategy in this study — auto-allo — was not enough to cure most patients. The disease tends to return quickly, and prevention of relapse is now a major priority.

Maintenance After Transplant: Two Open Questions

The editorial identifies two interlinked questions that emerge when considering maintenance therapy after auto-allo:

1. Would the advantage of auto-allo persist with maintenance? In other words, could adding a maintenance drug make an already promising strategy even more effective?
2. Would maintenance be feasible in the context of GvHD? Patients who develop GvHD after transplant can have fragile immune systems and may not tolerate additional medications.

On the first question, the editorial admits that there is no data yet — it is simply impossible to answer without further research.

On the second question, there is some evidence borrowed from myeloma studies. Lenalidomide is the only approved maintenance therapy for myeloma. It is an immunomodulatory drug that helps the immune system fight cancer cells. However, lenalidomide can worsen GvHD.

Several points emerge from the editorial's discussion of the evidence:

• Studies have explored reduced lenalidomide dosing after transplant to lessen its negative effect on GvHD.
• Even so, giving lenalidomide after an allogeneic transplant "can remain challenging," the editorial notes.
• The LenaRIC study (Cook et al., 2017), a UK NCRI phase 2 feasibility trial, showed that reduced-intensity stem cell transplantation followed by lenalidomide was tolerable, safe, and improved the complete response rate in multiple myeloma.

A different maintenance drug may offer a better path forward. Bortezomib, a proteasome inhibitor commonly known by the brand name Velcade, was tested in a recent phase II study by LeBlanc and colleagues, published in Bone Marrow Transplantation in 2022. That trial explored bortezomib maintenance after tandem auto-allo transplant in young and/or high-risk myeloma patients. The results were encouraging: better progression-free and overall survival, and lower rates of GvHD than in historic controls.

Bortezomib maintenance is particularly interesting because it does not appear to fuel GvHD the way lenalidomide can. Whether this approach will translate to pPCL patients remains to be seen, but the editorial views it as a promising avenue.

The Graft-Versus-Host Disease Barrier

Concern about GvHD is not just a side effect issue. The editorial suggests it is "probably one of the main barriers to wider utilization of auto-allo transplants in pPCL and myeloma." Why? Because GvHD can complicate everything that comes after the transplant — including maintenance treatment and even the newer immunotherapies that patients may need later.

If doctors could manage GvHD more effectively, they might be more willing to recommend auto-allo transplants. There is some reason for hope on this front.

The editorial cites the work of Zeiser and colleagues, published in the New England Journal of Medicine in 2020, showing that the drug ruxolitinib is effective for glucocorticoid-refractory acute graft-versus-host disease — that is, acute GvHD that does not improve with steroid treatment. Ruxolitinib belongs to a class of drugs called JAK inhibitors.

Whether such general improvements in GvHD management will make post-allo therapy more deliverable for pPCL patients is still unknown. The editorial concludes on this point with cautious wording: it "is yet to be seen."

Future Treatment Options: New Immunotherapies

The transplant data must now be viewed in the context of a rapidly evolving treatment landscape for myeloma — and, potentially, pPCL. The editorial surveys several novel approaches.

Daratumumab is a monoclonal antibody (a lab-engineered protein that targets specific cells) directed against CD38, a protein found on the surface of myeloma and leukemia cells. When daratumumab was combined into an intensive regimen known as Dara-CVRd — daratumumab plus bortezomib, lenalidomide, cyclophosphamide, and dexamethasone — it demonstrated promising responses in pPCL patients in the OPTIMUM/MUKnine trial.

Even more advanced immunotherapies are now on the scene:

• Chimeric antigen receptor (CAR) T-cell therapies — treatments in which a patient's own immune T cells are collected, genetically engineered to recognize cancer cells, and infused back into the patient. The drug ciltacabtagene autoleucel, tested in the CARTITUDE-1 trial published in The Lancet in 2021, is an example of this approach targeting the protein BCMA (B-cell maturation antigen), which is found on myeloma cells.
• Antibody-drug conjugates — monoclonal antibodies attached to a chemotherapy drug, which deliver the toxic payload directly to cancer cells. Versions targeting BCMA have already received regulatory approval for myeloma.
• T-cell engager monoclonal antibodies — antibody-based drugs that physically link immune T cells to cancer cells, forcing an attack. Approvals for agents against multiple targets are pending.

The editorial strikes an important note of caution: the activity and safety of these novel approaches "are still to be established in pPCL." Just because a drug works for myeloma does not guarantee it will work for plasma cell leukemia, which behaves more aggressively.

Clinical Trials That Include pPCL Patients

More trials that include pPCL patients are urgently needed, the editorial argues. Historically, many trials excluded pPCL or lumped it together with other forms of the disease without reporting results separately.

Two trials stand out as examples of the feasibility of inclusive approaches:

• SWOG-1211 — a randomized phase 2 trial that enrolled both pPCL and high-risk myeloma patients. It tested bortezomib, lenalidomide, and dexamethasone with or without elotuzumab, a monoclonal antibody targeting the protein SLAMF7. Its primary analysis was published in The Lancet Haematology in 2021.
• OPTIMUM/MUKnine — a UK trial with a screening component to identify high-risk patients, combined with a phase II study evaluating an optimized combination of biological therapy in newly diagnosed high-risk myeloma and plasma cell leukemia. The protocol was published in BMJ Open in 2021.

A third trial, EMN12/HOVON129, tested a carfilzomib and lenalidomide-based regimen specifically for pPCL. Its first interim analysis was presented in 2019 at the American Society of Hematology annual meeting. Collectively, these studies show that enrolling pPCL patients in rigorous trials is possible.

Clinical Implications: What This Means for Patients

Every section of this editorial analysis points to one conclusion: patients with pPCL need personalized, expert decision-making.

The registry data provide "very useful information on the value of tandem auto-allo in pPCL," the editorial states — especially for carefully selected, younger patients. The key phrase is "carefully selected." Auto-allo is a demanding treatment. It offers the best progression-free survival in this analysis, but it also carries the risks of donor cells: GvHD, infections, and treatment-related mortality.

Several practical points follow:

• Achieving a complete response before transplant appears to change which strategy is best. Patients in CR may do well with tandem auto-auto, avoiding donor-related complications.
• Patients not in CR after induction may benefit more from the graft-versus-leukemia effect — the immune attack that donor cells mount against the cancer — which is the theoretical advantage of including an allogeneic transplant.
• Even after a successful auto-allo transplant, relapse within 2 to 3 years remains common. Maintenance therapy is an urgent unmet need.
• New immunotherapies are transforming myeloma, but their role in pPCL is not yet proven. Access to clinical trials is therefore critically important.

Limitations: What This Study Couldn't Prove

Patients should understand the limits of this evidence when weighing treatment decisions:

• Retrospective registry data. This was not a randomized controlled trial. The researchers adjusted for measured differences between patient groups, but unmeasured factors may still have influenced the results.
• The pre-maintenance era. Treatments occurred between 1998 and 2014. Modern induction regimens are stronger, and no maintenance drugs were routinely used then. Results may differ with contemporary care.
• Statistically non-significant findings. Overall survival was nominally better with tandem approaches, but the difference did not reach statistical significance. The same was true for auto-auto versus single auto in progression-free survival.
• Modeling-based subgroup findings. The insights about complete response timing came from dynamic prediction modeling, not from direct randomized comparisons.
• Unanswered maintenance questions. Whether maintenance after auto-allo would preserve the survival advantage, and whether it is feasible alongside GvHD, remains unknown.
• Limited evidence for novel therapies. CAR T-cell therapy, antibody-drug conjugates, and T-cell engagers are approved or pending approval for myeloma, but their safety and activity in pPCL have not been established.

These limitations do not diminish the study's value. In a disease this rare, well-analyzed registry data may be the best evidence available for years to come.

Recommendations for Patients and Families

If you or a loved one has been diagnosed with primary plasma cell leukemia, here are actionable steps to consider based on this editorial:

1. Seek a specialized center. pPCL is rare, and treatment outcomes depend heavily on experience. Ask whether your hospital participates in transplant registries and clinical trials for this disease.
2. Ask about your complete response status. The study suggests that response to induction therapy should influence transplant strategy. Ask your doctor: "If I achieve complete remission, would my transplant options change?"
3. Discuss the auto-allo option explicitly. Tandem auto-allo transplant appears to offer the greatest progression-free survival improvement over a single autologous transplant, and the editorial sees its value particularly for carefully selected, younger patients. It comes with real risks, and only your transplant team can judge whether you are a good candidate.
4. Raise the topic of maintenance early. Most patients relapse within 2 to 3 years after transplant. Planning a maintenance strategy before, not after, transplant is worth discussing.
5. Ask about clinical trials. Trials like SWOG-1211, OPTIMUM/MUKnine, and EMN12/HOVON129 have shown that research studies can include pPCL patients. Ask whether any open trial is appropriate for your situation.
6. Keep track of new immunotherapy approvals. Daratumumab-based combinations, BCMA-targeted CAR T-cell therapy, antibody-drug conjugates, and T-cell engagers are changing myeloma care. Their use in pPCL is emerging, and your doctor can help you understand when these options might apply.

Frequently Asked Questions

What is primary plasma cell leukemia?

Primary plasma cell leukemia (pPCL) is a rare and aggressive blood cancer. It is a much more aggressive version of multiple myeloma, a cancer of plasma cells, the antibody-producing white blood cells that normally live in the bone marrow. In pPCL, malignant plasma cells escape the bone marrow and circulate in the bloodstream. It is severely understudied, with few evidence-based treatment options.

What are the risks of a tandem auto-allo transplant?

Auto-allo carries the risks of donor cells, including graft-versus-host disease (GvHD), infections, and treatment-related mortality. GvHD occurs when donor immune cells attack healthy tissues; it can be acute or chronic and may affect skin, liver, mouth, eyes, and other organs. The editorial calls GvHD probably one of the main barriers to wider use of auto-allo transplants.

What new treatments are being studied for pPCL?

New immunotherapies are changing myeloma care and may one day help pPCL, but their activity and safety in pPCL are still to be established. These include daratumumab-based combinations, BCMA-targeted CAR T-cell therapies, antibody-drug conjugates, and T-cell engager antibodies. Clinical trials that include pPCL patients, such as SWOG-1211, OPTIMUM/MUKnine, and EMN12/HOVON129, are urgently needed.

When should a patient with primary plasma cell leukemia seek a second opinion about transplant strategy?

Because pPCL is rare and understudied, treatment decisions are complex. A second opinion can help when weighing tandem auto-allo transplant, which improved progression-free survival in a registry analysis of 751 patients, against single or tandem auto-auto approaches. It is also worth seeking when complete response status after induction might change which strategy fits, or when discussing maintenance and clinical trials. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on peer-reviewed research. The original publication is an editorial commentary:

• Original title: "A double punch for plasma cell leukemia"
• Author: Martin Kaiser, The Institute of Cancer Research, The Royal Marsden Hospital, London, UK
• Journal: Haematologica, Volume 108, April 2023, pages 939–940
• DOI: https://doi.org/10.3324/haematol.2022.281353
• Received: May 31, 2022; Accepted: June 21, 2022; Early view: June 30, 2022
• Publisher: Ferrata Storti Foundation, published under a CC BY-NC license

The editorial comments on the companion research article by Lawless S, Iacobelli S, Knelange NS, and colleagues: "Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling," published in Haematologica, Volume 108, Issue 4 (2023), pages 1105–1114.

Financial disclosures for transparency: The editorial author, Martin Kaiser, has received consultancy fees and travel support from Janssen, BMS, and Takeda; consultancy fees from AbbVie, Pfizer, Seattle Genetics, and GSK; consultancy fees and honoraria from Amgen; and consultancy fees and research funding from Karyopharm, Janssen, and Celgene Corporation.

This article is adapted for patients and is not a substitute for professional medical advice. Always discuss your individual treatment plan with your hematology and transplant teams.